Glaxosmithkline Share Price | |
---|---|
Price | 1,503.50 |
Bid | 1,502.50 |
Ask | 1,504.00 |
Change | 0.00 (0.00%) |
Volume | 0 |
Open | 0.00 |
High | 0.00 |
Low | 0.00 |
Prev. Close | 1,503.50 |
Currency | GBX |
---|---|
Issue Country | GB |
Shares in Issue | 4.08b |
Market Capitalisation | £61.31b |
Market Size | 1,500 |
52 Week High | 1,820.00 |
52 Week High Date | 15-May-2024 |
52 Week Low | 1,302.60 |
52 Week Low Date | 11-Jul-2023 |
# Trades | 0 |
---|---|
Vol. Sold | 0 |
Sold Value | £N/A |
Vol. Bought | 0 |
Bought Value | £N/A |
PE Ratio | 12.36431 |
Earnings | 121.60 |
Dividend | 55.50 |
Yield | 3.691% |
Date | Time | Trade Prc | Volume | Buy/Sell | Bid | Ask | Value | |
---|---|---|---|---|---|---|---|---|
02-Jul-24 | 16:17:42 | 1,500.50 | 6 | Unknown* | 1,502.50 | 1,504.00 | 90.03 | O Ordinary Delayed publication Was reported as OTC |
02-Jul-24 | 16:16:35 | 1,501.00 | 0 | Unknown* | 1,502.50 | 1,504.00 | 0.00 | O Ordinary Delayed publication Was reported as OTC |
02-Jul-24 | 16:13:23 | 1,501.50 | 0 | Unknown* | 1,502.50 | 1,504.00 | 0.00 | O Ordinary Delayed publication Was reported as OTC |
02-Jul-24 | 16:50:01 | 1,503.50 | 1,067 | Buy* | 1,502.50 | 1,504.00 | 16.04k | O Ordinary |
02-Jul-24 | 16:37:14 | 1,503.50 | 7,105 | Buy* | 1,502.50 | 1,504.00 | 106.82k | A Automatic Execution |
02-Jul-24 | 16:37:14 | 1,503.50 | 7,500 | Buy* | 1,502.50 | 1,504.00 | 112.76k | A Automatic Execution |
02-Jul-24 | 16:37:14 | 1,503.50 | 2,580 | Buy* | 1,502.50 | 1,504.00 | 38.79k | A Automatic Execution |
02-Jul-24 | 16:35:17 | 1,503.50 | 16,758 | Unknown* | 1,502.50 | 1,504.00 | 251.96k | O Ordinary Was reported as OTC |
02-Jul-24 | 16:35:17 | 1,503.50 | 4,583 | Unknown* | 1,502.50 | 1,504.00 | 68.91k | O Ordinary Was reported as OTC |
02-Jul-24 | 16:35:17 | 1,503.50 | 173 | Unknown* | 1,502.50 | 1,504.00 | 2,601 | O Ordinary Was reported as OTC |
Announced | Traded | Action | Notifier | Price | Currency | Amount | Holding |
---|---|---|---|---|---|---|---|
21-Jun-24 | 20-Jun-24 | Buy | Jonathan Symonds held the position of Non-Executive Chairman at the time of this trade.Jonathan Symonds | 1,614.53 | GBX | 2,000 | 56,143 |
21-Jun-24 | 20-Jun-24 | Buy | Jesse Goodman held the position of Independent Non-Executive Director at the time of this trade.Jesse Goodman | 40.76 | USD | 225 | 11,382 |
21-Jun-24 | 20-Jun-24 | Buy | Jeannie Lee held the position of Non-Executive Director at the time of this trade.Jeannie Lee | 40.76 | USD | 293 | 293 |
21-Jun-24 | 20-Jun-24 | Buy | Harry (Hal) C. Dietz held the position of Independent Non-Executive Director at the time of this trade.Harry (Hal) C. Dietz | 40.76 | USD | 225 | 3,343 |
21-Jun-24 | 20-Jun-24 | Buy | Anne Beal held the position of Independent Non-Executive Director at the time of this trade.Anne Beal | 40.76 | USD | 225 | 3,600 |
At GSK, we unite science, technology and talent to get ahead of disease together